MedPath

Psychoeducation for Uveal Melanoma

Not Applicable
Active, not recruiting
Conditions
Uveal Melanoma
Interventions
Behavioral: Education for Intervention
Behavioral: Best Practice
Registration Number
NCT06075589
Lead Sponsor
Jonsson Comprehensive Cancer Center
Brief Summary

This clinical trial evaluates a video-based psychoeducational intervention for patients with uveal melanoma. Uveal melanoma (UM) is a rare intraocular cancer. UM patients face an uncertain course of survivorship in terms of their visual acuity, treatment-related side effects, and risk for eventual metastasis of the cancer. Learning about patients' thoughts and reactions to informational resources may better support patients during ocular melanoma survivorship.

Detailed Description

PRIMARY OBJECTIVE:

I. To assess the efficacy of the psychoeducation intervention (compared to the control condition) in modifying illness perceptions of disease control, chronicity, and coherence (i.e., to become less threatening) over the course of the follow-up period.

SECONDARY OBJECTIVE:

I. To assess the efficacy of the psychoeducation intervention (compared to the control condition) in reducing the degree of participant's depressive and anxiety symptoms over the course of the follow-up period.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.

ARM II: Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
108
Inclusion Criteria
  • Adults (age 18 years and older at visit 1)
  • History of uveal melanoma as documented in their University of California, Los Angeles (UCLA) medical record
  • Receipt of uveal melanoma treatment and/or ongoing follow-up care at the UCLA Jules Stein Eye Institute, as documented in their UCLA medical record
  • Ability to read, write, and converse in English
  • Access to the internet via a computer or cell phone
  • Access to a personal email address
  • Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Arm 1Education for InterventionParticipants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
Arm IIBest PracticePatients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
Primary Outcome Measures
NameTimeMethod
Change in illness perceptions of chronicityFrom baseline to day 77

Will be assessed using the BIPQ will be examined across treatment and control conditions using multilevel models.

Change in illness perceptions of disease controlFrom baseline to day 77

Will be assessed using the Brief Illness Perception Questionnaire (BIPQ) and will be examined across treatment and control conditions using multilevel models.

Change in illness perceptions of coherenceFrom baseline to day 77

Will be assessed using the BIPQ will be examined across treatment and control conditions using multilevel models.

Secondary Outcome Measures
NameTimeMethod
Domains of mental health: DepressionFrom baseline to day 77

Will be assessed by multilevel models of depression symptoms as functions of treatment condition (i.e., group assignment). Depressive symptoms will be assessed at all assessment points with the well-validated 20-item Center for Epidemiologic Studies-Depression Scale.

Domains of mental health: AnxietyFrom baseline to day 77

Will be assessed by multilevel models of anxiety symptoms as functions of treatment condition (i.e., group assignment). Anxiety symptoms will be assessed at all assessment points with the Generalized Anxiety Disorder Scale-7.

Trial Locations

Locations (1)

University of California at Los Angeles

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath